Virginia Mela

Dr. Virginia Mela

University of Malaga, Faculty of Medicine
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
RHR. Holland
R. Holland
AMA.L. McIntosh
A.L. McIntosh
OFO.M. Finucane
O.M. Finucane
VMVirginia Mela
Virginia Mela
ARA. Rubio-Araiz
A. Rubio-Araiz
MLMarina A Lynch
Marina A Lynch

10 June 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
MGMarie-Victoire Guillot-Sestier
Marie-Victoire Guillot-Sestier
AAAna Rubio Araiz
Ana Rubio Araiz
VMVirginia Mela
Virginia Mela
AGAline Sayd Gaban
Aline Sayd Gaban
EOEoin O’neill
Eoin O’neill
MLMarina A Lynch
Marina A Lynch
Age and sex are major risk factors in Alzheimer’s disease (AD) with a higher incidence of the disease in females. Neuroinflammation, which is a hallmark of AD, contributes to disease pathogenesis and is inexorably linked with inappropriate microglial activation and neurodegeneration. We investigated sex-related differences in microglia in APP/PS1 mice and in post-mortem tissue from AD patients. Changes in genes that are indicative of microglial activation were preferentially increased in cells from female APP/PS1 mice and cells from males and females were morphological, metabolically and functionally distinct. Microglia from female APP/PS1 mice were glycolytic and less phagocytic and associated with increased amyloidosis whereas microglia from males were amoeboid and this was also the case in post-mortem tissue from male AD patients, where plaque load was reduced. We propose that the sex-related differences in microglia are likely to explain, at least in part, the sexual dimorphism in AD.

20 January 2019 in Brain Pathology
Verified
Journal Article
Open access
PDF file
AMAllison McIntosh
Allison McIntosh
VMVirginia Mela
Virginia Mela
CHConor Harty
Conor Harty
AMAedin M. Minogue
Aedin M. Minogue
DCDerek Costello
Derek Costello
MLMarina A Lynch
Marina A Lynch
Among the changes that typify Alzheimer’s disease (AD) are neuroinflammation and microglial activation, amyloid deposition perhaps resulting from compromised microglial function and iron accumulation. Data from Genome Wide Association Studies (GWAS) identified a number of gene variants that endow a significant risk of developing AD and several of these encode proteins expressed in microglia and proteins that are implicated in the immune response. This suggests that neuroinflammation and the accompanying microglial activation are likely to contribute to the pathogenesis of the disease. The trigger(s) leading to these changes remain to be identified. In this study, we set out to examine the link between the inflammatory, metabolic and iron‐retentive signature of microglia in vitro and in transgenic mice that overexpress the amyloid precursor protein (APP) and presenilin 1 (PS1; APP/PS1 mice), a commonly used animal model of AD. Stimulation of cultured microglia with interferon (IFN)γ and amyloid‐β (Aβ) induced an inflammatory phenotype and switched the metabolic profile and iron handling of microglia so that the cells became glycolytic and iron retentive, and the phagocytic and chemotactic function of the cells was reduced. Analysis of APP/PS1 mice by magnetic resonance imaging (MRI) revealed genotype‐related hypointense areas in the hippocampus consistent with iron deposition, and immunohistochemical analysis indicated that the iron accumulated in microglia, particularly in microglia that decorated Aβ deposits. Isolated microglia prepared from APP/PS1 mice were characterized by a switch to a glycolytic and iron‐retentive phenotype and phagocytosis of Aβ was reduced in these cells. This evidence suggests that the switch to glycolysis in microglia may kick‐start a cascade of events that ultimately leads to microglial dysfunction and Aβ accumulation.

1 April 2015 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
EMEva M. Marco
Eva M. Marco
RLRicardo Llorente
Ricardo Llorente
MGMeritxell López Gallardo
Meritxell López Gallardo
VMVirginia Mela
Virginia Mela
ÁLÁlvaro Llorente-Berzal
Álvaro Llorente-Berzal
MVMaria-Paz Viveros
Maria-Paz Viveros

1 July 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
VMVirginia Mela
Virginia Mela
BMBibiana C. Mota
Bibiana C. Mota
MMMark Milner
Mark Milner
AMAoife McGinley
Aoife McGinley
KMKingston Mills
Kingston Mills
MLMarina A Lynch
Marina A Lynch

1 March 2012 in Neuropharmacology
Verified
Journal Article
Closed access
ALAlvaro Llorente-Berzal
Alvaro Llorente-Berzal
VMVirginia Mela
Virginia Mela
EBErika Borcel
Erika Borcel
MVManuel Valero
Manuel Valero
MGMeritxell López Gallardo
Meritxell López Gallardo
EMEva M. Marco
Eva M. Marco